Cargando…
Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients
BACKGROUND: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. METHODS: A retrospective study was carried out...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627413/ https://www.ncbi.nlm.nih.gov/pubmed/26514283 http://dx.doi.org/10.1186/s12885-015-1853-1 |
_version_ | 1782398290124341248 |
---|---|
author | Chen, Xiaosong Zhu, Siji Fei, Xiaochun Garfield, David H. Wu, Jiayi Huang, Ou Li, Yafen Zhu, Li He, Jianrong Chen, Weiguo Jin, Xiaolong Shen, Kunwei |
author_facet | Chen, Xiaosong Zhu, Siji Fei, Xiaochun Garfield, David H. Wu, Jiayi Huang, Ou Li, Yafen Zhu, Li He, Jianrong Chen, Weiguo Jin, Xiaolong Shen, Kunwei |
author_sort | Chen, Xiaosong |
collection | PubMed |
description | BACKGROUND: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. METHODS: A retrospective study was carried out on 276 patients with paired CNB and surgically removed samples (SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value change was calculated as SRS minus CNB. RESULTS: Mean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples: 29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 % within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+ tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed in patients with STI ≥ 5 days. CONCLUSION: CNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to consider Ki67 changes following CNB among different breast cancer molecular subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1853-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4627413 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46274132015-10-31 Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients Chen, Xiaosong Zhu, Siji Fei, Xiaochun Garfield, David H. Wu, Jiayi Huang, Ou Li, Yafen Zhu, Li He, Jianrong Chen, Weiguo Jin, Xiaolong Shen, Kunwei BMC Cancer Research Article BACKGROUND: To investigate the accuracy of core needle biopsy (CNB) in evaluating breast cancer estrogen receptor (ER), progesterone receptor (PR), HER2, and Ki67 status and to identify factors which might be associated with Ki67 value change after CNB. METHODS: A retrospective study was carried out on 276 patients with paired CNB and surgically removed samples (SRS). Clinico-pathological factors as well as the surgery time interval (STI) between CNB and surgery were analyzed to determine whether there were factors associated with Ki67 value change after CNB. Five tumor subtypes were classified as follows: Luminal A, Luminal B-HER2-, Luminal B-HER2+, Triple Negative (TN), and HER2+. Ki67 value change was calculated as SRS minus CNB. RESULTS: Mean STI after CNB was 4.5 (1-37) days. Good agreement was achieved for ER, PR, and HER2 evaluation between CNB and SRS. However, Ki67 expression level was significantly higher in SRS compared with CNB samples: 29.1 % vs. 26.2 % (P < 0.001). Both univariate and multivariate analysis demonstrated that STI and molecular subtype were associated with a Ki67 change after CNB. Luminal A tumors experienced more Ki67 elevation than Luminal B-HER2- diseases (6.2 % vs -0.1 %, P = 0.014). Patients with longer STI after CNB had a higher Ki67 increase: -1.1 % within 1-2 days, 2.1 % with 3-4 days, and 5.6 % more than 4 days, respectively (P = 0.007). For TN and HER2+ tumors, the Ki67 change was apt to be 0 with STI ≤ 4 days, while a >7 % Ki67 increase was noticed in patients with STI ≥ 5 days. CONCLUSION: CNB was accurate in evaluating ER, PR, HER2, and molecular subtype status. Ki67 value significantly increased after CNB, which was associated with STI and molecular subtype. Further translational research needs to consider Ki67 changes following CNB among different breast cancer molecular subtypes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1853-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-30 /pmc/articles/PMC4627413/ /pubmed/26514283 http://dx.doi.org/10.1186/s12885-015-1853-1 Text en © Chen et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Chen, Xiaosong Zhu, Siji Fei, Xiaochun Garfield, David H. Wu, Jiayi Huang, Ou Li, Yafen Zhu, Li He, Jianrong Chen, Weiguo Jin, Xiaolong Shen, Kunwei Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
title | Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
title_full | Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
title_fullStr | Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
title_full_unstemmed | Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
title_short | Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients |
title_sort | surgery time interval and molecular subtype may influence ki67 change after core needle biopsy in breast cancer patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627413/ https://www.ncbi.nlm.nih.gov/pubmed/26514283 http://dx.doi.org/10.1186/s12885-015-1853-1 |
work_keys_str_mv | AT chenxiaosong surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT zhusiji surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT feixiaochun surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT garfielddavidh surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT wujiayi surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT huangou surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT liyafen surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT zhuli surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT hejianrong surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT chenweiguo surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT jinxiaolong surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients AT shenkunwei surgerytimeintervalandmolecularsubtypemayinfluenceki67changeaftercoreneedlebiopsyinbreastcancerpatients |